The FDA has cleared the Epitomee capsule to support weight management in adults with a body mass index of 25 to 40kg/m2.

Biological age vs chronological age was younger among postmenopausal female individuals who received hormone replacement therapy.

The FDA has updated the prescribing information for Veozah (fezolinetant) to include a warning regarding the risk of serious liver injury.

Among participants with no history of major psychopathology, there is no association between semaglutide and depression and suicidality.